937799-91-2

Usage

Uses

Used in Oncology:
Olaparib, KU-0059436 is used as a targeted cancer therapy for the treatment of certain types of ovarian and breast cancer. Olaparib, as a PARP inhibitor, interferes with the DNA repair process in cancer cells, leading to their destruction. KU-0059436, as a selective inhibitor of Chk1, enhances the sensitivity of cancer cells to chemotherapy and radiation therapy, making it a potential target for cancer treatment.
Used in Drug Development:
Olaparib, KU-0059436 is used in the development of novel targeted cancer therapies. The combination of PARP inhibitors and Chk1 inhibitors represents a promising approach for the treatment of various types of cancer. Researchers are investigating the potential synergistic effects of these compounds and their potential to overcome drug resistance in cancer cells.
Used in Cancer Research:
Olaparib, KU-0059436 is used in cancer research to better understand the mechanisms of action of PARP inhibitors and Chk1 inhibitors. By studying the effects of these compounds on cancer cells, researchers can gain insights into the molecular pathways involved in cancer development and progression, and identify potential targets for the development of new cancer therapies.
Used in Drug Combination Therapy:
Olaparib, KU-0059436 is used in combination therapy for the treatment of cancer. The combination of PARP inhibitors and Chk1 inhibitors has shown potential synergistic effects in enhancing the sensitivity of cancer cells to chemotherapy and radiation therapy. This approach may improve treatment outcomes and overcome drug resistance in cancer patients.
Used in Personalized Medicine:
Olaparib, KU-0059436 is used in personalized medicine to develop targeted cancer therapies based on the genetic profile of individual patients. By identifying specific genetic mutations and molecular markers in cancer cells, researchers can develop tailored treatment strategies that are more effective and have fewer side effects for patients.